Biothermosetting Bone Filler: An Injectable Osteoconductive Repair Material
Funder
National Health and Medical Research Council
Funding Amount
$601,698.00
Summary
Bone injury is a common and profoundly debilitating issue, and is responsible for extended partial or complete loss of mobility and associated economic impact during slow healing. There is strong demand for technology that reduces the time taken for bone repair. There is still a paucity of clinically effective biocompatible materials for treatment. We have developed a novel approach for a thermoresponsive hydrogel with unique properties suitable for rapid bone filling and regeneration.
Anticalins: Inhalable Biologicals For Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$577,933.00
Summary
This grant aims to develop a new class of medicines called 'anticalins'. Anticalins behave like a successful class of medicines called monoclonal antibodies (mAbs). MAbs are too fragile and large to be inhaled to treat lung disease but anticalins are small and robust. We will be developing an anticalin (PRS-060) which blocks damaging immune reactions in severe asthma. By inhaling PRS-060 we hope to make a new and clinically useful medicine for a common form of poorly-controlled severe asthma.
Preclinical Validation Of First In Man Endovascular Brain Machine Interface Device
Funder
National Health and Medical Research Council
Funding Amount
$870,000.00
Summary
The stentrode technology has been given significant public attention, following publication in the fourth highest impact factor journal 'Nature Biotechnology' and a public statement of endorsement by the President of the United States in 2016. The program now seeks to conduct a preclinical validation program to satisfy the FDA in its requirements to provide Investigational Device Exemption (IDE).
Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation To Improve Antibody Drug Conjugate Production And Performance
Funder
National Health and Medical Research Council
Funding Amount
$402,046.00
Summary
Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.
Black Out Advisory System - Development Of An Implantable Sub-scalp Seizure Monitor
Funder
National Health and Medical Research Council
Funding Amount
$868,402.00
Summary
Blackouts may result from seizures or heart problems, and incorrect diagnosis exposes patients to risk and limits activities. Diagnosis is difficult because these events are infrequent. Implantable monitors are useful in diagnosing cardiac abnormalities, but prolonged seizure monitoring has not been feasible. This system will use a minimally invasive implant inserted under the scalp enabling distinction of epileptic from non-epileptic causes. The implant also has the capability to improve patien ....Blackouts may result from seizures or heart problems, and incorrect diagnosis exposes patients to risk and limits activities. Diagnosis is difficult because these events are infrequent. Implantable monitors are useful in diagnosing cardiac abnormalities, but prolonged seizure monitoring has not been feasible. This system will use a minimally invasive implant inserted under the scalp enabling distinction of epileptic from non-epileptic causes. The implant also has the capability to improve patient safety through remote monitoring.Read moreRead less
Development Of A High Acuity, Diamond Retinal Prosthesis
Funder
National Health and Medical Research Council
Funding Amount
$1,010,214.00
Summary
Over recent years our team has developed a retinal implant to restore sight to people with certain types of blindness. With 256 independently controllable electrodes this device is among the most sophisticated in the world. We aim to conduct experiments to demonstrate that our device can provide improved better visual acuity than the world leaders with a view to developing a competitive commercial medical technology.
Development Of Stable Human Antibody Phage Display Libraries
Funder
National Health and Medical Research Council
Funding Amount
$539,644.00
Summary
Antibodies are blockbuster therapeutics for the treatment of cancer and inflammation. Unfortunately, they often display limited stability which greatly hinders development and production. This project focuses on the construction of large libraries of stable antibodies, thereby streamlining the development of new therapeutics.
Needle Free Delivery Of Dengue And Zika Vaccines To The Skin
Funder
National Health and Medical Research Council
Funding Amount
$642,792.00
Summary
There is no Zika vaccine and only one licensed dengue vaccine, which is age and region restricted because of poor efficacy. We have developed safe subunit vaccine candidates capable of inducing potent virus neutralizing antibodies and demonstrated protection from lethal dengue challenge in a mouse model. Here we are partnering with Vaxxas to undertake preclinical development and GLP toxicity trials for microarray patches delivering dengue and zika virus subunit vaccines.
Skin Patch Technology For Fast And Simple Monitoring Of Disease
Funder
National Health and Medical Research Council
Funding Amount
$826,064.00
Summary
Micropatch kits will be developed to capture and detect disease-related biomarkers from the skin for diagnostic monitoring, without the need for needles, trained practitioners or expensive laboratory infrastructure
Developing A Prototype Of A Next Generation Brain Computer Interface
Funder
National Health and Medical Research Council
Funding Amount
$837,398.00
Summary
Persons affected by quadriplegia and hemiplegia from stroke and spinal cord injury have few treatment options. Brain Machine Interfaces reconnect brain to a prosthetic limb, bypassing damaged nervous system. Our group has developed a BMI that can be implanted minimally-invasively, inside a blood vessel in the brain. We propose to manufacture a world-first device for a human clinical trial pilot study. The aim is to restore mechanical control over the physical environment for a paralysed patient.